SPVN 30
Alternative Names: SPVN-30; SPVN06/20; SPVN20/06Latest Information Update: 31 Mar 2023
At a glance
- Originator SparingVision
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Retinitis pigmentosa
Most Recent Events
- 29 Mar 2023 Early research in Retinitis pigmentosa in France (Ophthalmic) (SparingVision pipeline, March 2023)